Search

Displaying results 4081 - 4090 of 10000 in total
  1. Drug

    Salclobuzic acid

    go.drugbank.com/drugs/DB19931
    Experimental

    Salclobuzic acid is a small molecule drug. Salclobuzic acid has a monoisotopic molecular weight of 257.05 Da.

  2. Drug

    Clamidoxic acid

    go.drugbank.com/drugs/DB19938
    Experimental

    Clamidoxic acid is a small molecule drug. Clamidoxic acid has a monoisotopic molecular weight of 339.01 Da.

  3. Drug

    Sulfaloxic acid

    go.drugbank.com/drugs/DB19971
    Experimental

    Sulfaloxic acid is a small molecule drug. Sulfaloxic acid has a monoisotopic molecular weight of 393.06 Da.

  4. Drug

    Sorbitan monopalmitate

    go.drugbank.com/drugs/DB20199
    Experimental

    Sorbitan monopalmitate is a small molecule drug. Sorbitan monopalmitate has a monoisotopic molecular weight of 402.3 Da.

  5. Drug

    Napsagatran anhydrous

    go.drugbank.com/drugs/DB20288
    Experimental

    Napsagatran anhydrous is a small molecule drug. Napsagatran anhydrous has a monoisotopic molecular weight of 558.23 Da.

    Categories: Heterocyclic Compounds, 1-Ring
  6. Drug

    Olpadronic acid

    go.drugbank.com/drugs/DB20303
    Investigational

    Olpadronic acid is a small molecule drug. Olpadronic acid has a monoisotopic molecular weight of 263.03 Da.

  7. Drug

    Caldaret

    go.drugbank.com/drugs/DB06231
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  8. Drug

    Abatacept

    go.drugbank.com/drugs/DB01281
    ApprovedInvestigational

    [L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each … The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes.

    Categories: Selective T Cell Costimulation ModulatorProducts: ORENCIA® SOLUCION INYECTABLE PARA ADMINISTRACION SUBCUTÁNEA 125 MG/ML, ORENCIA® 250 MG - POLVO LIOFILIZADO PARA SOLUCIÓN INYECTABLE INTRAVENOSA
  9. Drug

    Lofexidine

    go.drugbank.com/drugs/DB04948
    ApprovedInvestigational

    Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. … [T210] Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine.

    Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesSynonyms: 2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline
  10. Drug

    anti-OX40 antibody BMS 986178

    go.drugbank.com/drugs/DB15773
    Investigational

    A macrocyclic peptide (BMS-986189) with activity in binding and functional assays comparable to a PD-L1 antibody.